National Healthcare Corporation FY2024 Financial Report: Revenue Increased 15.2%

Executive Summary

For the fiscal year ending December 31, 2024, National Healthcare Corporation (NHC) demonstrated robust growth driven primarily by a 15.2% increase in total revenues, reaching approximately $1.31 billion compared to $1.14 billion in the previous year. Net income attributable to shareholders rose significantly by 52.7%, from $66.8 million to $102.1 million, reflecting improved operational efficiencies and favorable market conditions. The company’s strong cash flow from operations, totaling $107.3 million, supports ongoing investments and shareholder returns. The balance sheet remains solid with total assets of $1.52 billion and a healthy liquidity position, although leverage increased slightly due to strategic acquisitions and debt issuance. Overall, NHC’s performance indicates a positive outlook with expanding revenue streams and improving profitability metrics.

Key Metrics

Management Discussion and Analysis

During FY2024, NHC capitalized on strategic acquisitions, notably the White Oak Senior Living Portfolio, which contributed approximately $96.1 million in revenue since acquisition. The company’s focus on expanding its skilled nursing and assisted living facilities has resulted in increased patient volumes and improved reimbursement rates, supporting revenue growth. Operating expenses increased modestly by 12.4%, primarily due to higher staffing costs and facility maintenance, but margins improved due to operational efficiencies. The company also benefited from unrealized gains on marketable securities, adding approximately $30.96 million to non-operating income, which bolstered net income. The balance sheet reflects a strong liquidity position with over $76 million in cash and cash equivalents, although leverage has increased with new debt issuance to fund acquisitions and capital expenditures.

Income Statement Analysis

Revenues increased by 15.2%, driven by a 16.4% rise in net patient revenues from $1.09 billion to $1.25 billion. Gross profit margins improved slightly due to better cost management, with gross profit reaching approximately $308.6 million. Operating income grew by 50.2%, from $57.1 million to $85.8 million, supported by higher revenue and controlled operating expenses. Net income attributable to shareholders surged by 52.7%, from $66.8 million to $102.1 million, reflecting both operational improvements and favorable market gains. Earnings per share (diluted) increased from $4.34 to $6.53, indicating strong shareholder value creation.

Balance Sheet Analysis

Assets grew by 16.2%, reaching $1.52 billion, primarily due to acquisitions and capital investments. Cash and cash equivalents declined slightly by 28.8%, from $107 million to $76 million, due to funding of acquisitions and share repurchases. Accounts receivable increased by 24.6%, reflecting higher patient volumes and billing activity. Property and equipment increased by 38.9%, reaching $684.3 million, driven by new facility construction and upgrades. Total liabilities increased to $541.3 million, with long-term debt of $137 million, up from zero in the prior year, mainly due to new borrowings for acquisitions. Shareholders’ equity increased by 8.0%, reaching $983.2 million, supported by retained earnings and accumulated other comprehensive income.

Cash Flow Analysis

Net cash provided by operating activities was $107.3 million, slightly lower than the previous year, mainly due to increased working capital needs. Investing activities used approximately $236.7 million, primarily for acquisitions and capital expenditures. Financing activities generated $100.3 million, mainly from new debt issuance and issuance of common stock, offset by share repurchases totaling $13.5 million and dividend payments of $36.9 million. The company’s capital expenditure program focused on expanding and upgrading existing facilities to support future growth. Dividends per share increased to $2.42, reflecting confidence in ongoing earnings growth.

Ratios & DuPont Analysis

Net profit margin improved to 7.8% from 5.8% in FY2023, driven by higher revenue and margin expansion. Return on assets (ROA) increased to 6.7% from 5.0%, indicating better asset utilization. Return on equity (ROE) rose to 10.4% from 7.3%, supported by higher net income and retained earnings. Asset turnover ratio remained stable at 0.86, while the equity multiplier increased to 1.55, reflecting higher leverage. These ratios collectively suggest a company with improving profitability and efficient asset management, albeit with increased financial leverage due to recent debt issuance.

Risk Factors

Key risks include regulatory changes impacting reimbursement rates, increased competition in the healthcare sector, operational risks related to staffing and facility management, and macroeconomic factors such as inflation and interest rate fluctuations. The company also faces potential legal liabilities from ongoing litigation and compliance risks associated with healthcare laws. Market volatility and changes in government policy could affect revenue streams and profitability.

Notes & Additional Commentary

Unusual items include a $1.02 million gain from the sale of an unconsolidated investment and unrealized gains on securities. The company’s strategic acquisitions have contributed significantly to revenue growth but also increased leverage. Share repurchases and dividend increases demonstrate management’s confidence in future earnings. No material impairments or one-time charges were recorded during FY2024.

Investment Implications

Investors should view NHC as a resilient healthcare provider with a strong growth trajectory driven by acquisitions and operational efficiencies. The increased leverage warrants attention, but the company’s solid cash flow and asset base support its long-term outlook. Short-term opportunities include capitalizing on favorable reimbursement trends and expanding service offerings. Long-term risks involve regulatory changes and market competition, which could impact margins. Overall, NHC presents a balanced risk-reward profile suitable for income-focused and growth-oriented investors.